about
Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.Recent advances in the understanding of antibiotic resistance in Clostridium difficile infectionConventional and alternative treatment approaches for Clostridium difficile infectionSingly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria.Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response.Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoeaNew Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development.Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.Is fidaxomicin worth the cost? An economic analysis.Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to Clostridium difficile colonization in mice.
P2860
Q24616179-E26CA838-AC8A-4C1D-A66E-42DB5FD01136Q26767079-8A06ADA1-6CE4-4F40-B8ED-7D337848C6D7Q30235278-F64AB0B6-9F35-40F3-AEA7-D3735DD0BA5CQ34982853-B543525E-81FC-4DE1-8B37-A879390A8813Q35044119-DD0424EB-5F69-4905-8494-8FAC29C7600CQ36019350-99EAA762-DCDF-4078-91F6-0EAF89916615Q36140398-2681D038-DCEB-4714-B305-9BB998E4061CQ36153263-D3412200-9FAE-4BE1-9343-71BDCA9DF957Q36984883-16471577-CFC4-48EF-B1B3-4BD772F6E14BQ37037009-65F27832-B3D6-4E6D-A11D-8864D99C4645Q37588248-2AC389CC-0C95-4BEB-904E-EF62342793F9Q38107547-45CC93F4-98C3-4C74-96C4-7E3C51999E0AQ42695041-3945894B-A253-41E0-B538-97046D4666F3Q48582947-AA449FF0-8CDB-4DF1-AC55-4E02E94BFA9DQ49792028-8EE58D61-0C8D-43E3-8714-B893038F6D7B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Fidaxomicin: first-in-class macrocyclic antibiotic.
@en
Fidaxomicin: first-in-class macrocyclic antibiotic.
@nl
type
label
Fidaxomicin: first-in-class macrocyclic antibiotic.
@en
Fidaxomicin: first-in-class macrocyclic antibiotic.
@nl
prefLabel
Fidaxomicin: first-in-class macrocyclic antibiotic.
@en
Fidaxomicin: first-in-class macrocyclic antibiotic.
@nl
P2860
P356
P1476
Fidaxomicin: first-in-class macrocyclic antibiotic.
@en
P2093
Kathleen M Mullane
Sherwood Gorbach
P2860
P304
P356
10.1586/ERI.11.53
P577
2011-07-01T00:00:00Z